/

Empresas

H.

No verificado

H. Lundbeck A/S

Sobre qué escribimos

AgriculturaFitnessMedicina - VariosMedio Ambiente/EcologíaSalud

20 Comunicados de prensa

Ver todos los comunicados de prensa

23/07/2026

Salud

Fitness

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy

Fuente

H. Lundbeck A/S

Editor

1.00

0

20/07/2026

Salud

Fitness

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)

Fuente

H. Lundbeck A/S

Editor

1.00

0

24/06/2026

Salud

Fitness

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Tarek Samad appointed EVP, Head of Research & Development at Lundbeck

Fuente

H. Lundbeck A/S

Editor

1.00

0

24/06/2026

Salud

Fitness

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026

Fuente

H. Lundbeck A/S

Editor

1.00

0

15/06/2026

Salud

Fitness

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026

Fuente

H. Lundbeck A/S

Editor

1.00

0

10/06/2026

Salud

Fitness

Ferias y Congresos

Eventos

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026

Fuente

H. Lundbeck A/S

Editor

1.00

0

04/06/2026

Salud

Fitness

Ferias y Congresos

Eventos

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

Fuente

H. Lundbeck A/S

Editor

1.00

0

26/05/2026

Salud

Fitness

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine

Fuente

H. Lundbeck A/S

Editor

1.00

0

18/05/2026

Salud

Fitness

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease

Fuente

H. Lundbeck A/S

Editor

1.00

0

19/04/2026

Salud

Fitness

Sociedad/Prensa del corazón

Crónica de sociedad

Medicina - Varios

Medio Ambiente/Ecología

Agricultura

Lundbeck presents new data at AAN 2026 highlighting real-world changes in migraine-related cognitive symptoms after starting VYEPTI® (eptinezumab)

Fuente

H. Lundbeck A/S

Editor

1.00

0

Seguidores

0

Compatibilidad

0